Expression of the type 1 metalloproteinase in the rat hippocampus after the intracerebroventricular injection of beta-amyloid peptide (25-35)

• Autorzy: Ierusalimsky V.N. , Kuleshova E. P. , Balaban P. M.
• Języki publikacji: EN

Abstrakty

EN

The expression of matrix metalloproteinase of the first type was studied in frontal sections of the adult rat brain one month after a single intracerebroventricular injection of P-amyloid peptide (25-35), which is known to be a well-known model of the development of Alzheimer's disease. Brain sections were stained immunocytochemically to detect MMP-1 expression, and histologically to reveal the state of hippocampal neurons. Administration of P-amyloid peptide induced a significant degeneration of cells in the dorsal hippocampus. This was demonstrated by a significant decrease in the total number of cells and by the appearance of acidophilic neurons of altered (often triangular) shape. Altered cells were most often found in the hippocampal field CA3, and in a smaller quantity in the CA1 field. MMP-1-like immunoreactivity was found in the same hippocampal areas, the staining being restricted to the cells of altered shape (staining of somata and primary neurites). The data suggest possible involvement of the type 1 metalloproteinase in the development of Alzheimer's disease.

Słowa kluczowe

EN

protein expression; metalloproteinase; rat; hippocampus; intracerebroventricular injection; beta-amyloid peptide

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2013
• Tom: 73
• Numer: 4
• Opis fizyczny: p.571-578,fig.,ref.

Twórcy

autor

Ierusalimsky V.N.

• Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia

autor

Kuleshova E. P.

• Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia

autor

Balaban P. M.

• Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia
• Lomonosov Moscow State University, Moscow, Russia

Bibliografia

• Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94: 239-247.
• Asashina M, Yoshiyama Y, Hattori T (2001) Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 20: 60-63.
• Backstrom JR, Lim GP, Cullen MJ, Tökes ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid- ß peptide (1- 40). J Neurosci 16: 7910¬7919.
• Bernstein HG, Ansorge S, Riederer P, Reiser M, Frölich L, Bogerts B (1999) Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett 263: 161¬164.
• Carpentier M, Robitaille Y, DesGroseillers L, Boileau G, Marcinkiewicz M (2002) Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61: 849-856.
• Deb S, Gottschall PE (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hip-pocampal cultures treated with beta-amyloid peptides. J Neurochem 66: 1641-1647.
• Del Bigio MR, Jacque CM (1995) Localization of proteinase expression in the developing rabbit brain. Brain Res Dev Brain Res 86: 345-347.
• Delobette S, Privat A, Maurice T (1997) In vitro aggregation facilitates beta-amyloid peptide-(25-35)-induced amne¬sia in the rat. Eur J Pharmacol 319: 1-4.
• Giovanelli L, Casamenti F, Scali C, Bartolini L, Pepeu G (1995) Differential effects of amyloid peptides ß-(1-40) and ß-(25-35) injections into the rat nucleus basalis. Neuroscience 66: 781-792.
• Hafez D, Huang JY, Huynh AM, Valtierra S, Rockenstein E, Bruno AM, Lu B, Des Groseillers, Masliah E, Marr RA (2011) Neprilysin-2 is an important ß-amyloid degrading enzyme. Am J Pathol 178: 306-312.
• Hamill CE, Goldshmidt A, Nicole O, McKeon RJ, Brat DJ, Traynelis SF (2005) Special lecture: glial reactivity after damage: implications for scar formation and neuronal recovery. Clin Neurosurg 52: 29-44.
• Hamill CE, Michael Caudle W, Richardson JR, Yuan H, Pennell KD, Greene JG, Miller GW, Traynelis SF (2007) Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein- coupled receptor protease-activated receptor 1. Mol Pharmacol 72: 653-664.
• Helbecque N, Hermant X, Cottel D, Amouyel P (2003) The role of matrix metalloproteinase-9 in dementia. Neurosci Lett 350: 181-183.
• Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
• Huang JY, Bruno AM, Patel CA, Huynh AM, Philibert KD, Glucksman MJ, Marr RA (2008) Human membrane metallo-endopeptidase-like protein (MMEL) degrades both Aß42 and Aß40. Neuroscience 155: 258-262.
• Ierusalimsky VN, Balaban PM (2013) Type 1 metalloprotei- nase is selectively expressed in adult rat brain and can be rapidly up-regulated by kainate. Acta Histochem 115: 816-826.
• Jourquin J, Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, Rivera S (2003) Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 18: 1507-1517.
• Kaczmarek L, Lapinska-Dzwonek J, Szymczak S (2002) Matrix metalloproteinases in the adult brain physiology: A link between c-Fos, AP-1 and remodeling of neuronal connections? EMBO J 21: 6643-6648.
• Leake A, Morris CM, Whateley J (2000) Brain matrix metal- loproteinase 1 levels are elevated in Alzheimer's disease. Neurosci Lett 291: 201-203.
• Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG (2000) Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 1: 530-535.
• Leppert D, Lindberg RLP, Kappos L, Leib SL (2001) Matrix metalloproteinases: multifunctional effectors of inflam¬mation in multiple sclerosis and bacterial meningitis. Brain Res Rev 36: 249-257.
• Lillie RD (1965) Histopathologic Technic and Practical Histochemistry. Blakiston, New York, NY.
• Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF (2002) Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tssue of Parkinson's disease. Exp Neurol 178: 13-20.
• Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 43: 191-196.
• Maurice T, Lockart BP, Privat A (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181¬193.
• Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Aß-degrading enzymes in Alzheimer's disease. Brain Pathol 18: 240-252.
• Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L (2006) Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51: 703-714.
• Pagenstecher A, Stalder AK, Campbell IL (1997) RNAse protection assays for the simultaneous and semiquantita¬tive analysis of multiple murine matrix metalloproteinase (MMP) and MMP inhibitor mRNAs. J Immunol Methods 206: 1-9.
• Paxinos G, Watson C (1998) The Rat Brain in Stereotaxic Coordinates. (Fourth Edition) Academic Press, Sydney, AU. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by ß-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13: 1676-1687.
• Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8: 205-216.
• Sekine-Aizawa Y, Hama E, Watanabe K, Tsubuki S, Kanai- Azuma M, Kanai Y, Arai H, Aizawa H, Iwata N, Saido TC (2001) Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum. Eur J Neurosci 13: 935¬948.
• Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766.
• Stepanichev MY, Moiseeva YV, Lazareva NA, Gulyaeva NV (2005) Studies of the effects of fragment (25-35) of beta-amyloid peptide on the behavior of rats in a radial maze. Neurosci Behav Physiol 35: 511-518.
• Stepanichev MYu, Zdobnova IM, Zarubenko II, Lazareva NA, Gulyaeva NV (2006) Studies of the effects of central administration of P-amyloid peptide (25-35): pathomor- phological changes in the hippocampus and impairment of spatial memory. Neurosci Behav Physiol 36: 101¬106.
• Stojic J, Hagemann C, Haas S, Herbold C, Kuhnel S, Gerngras S, Roggendorf W, Roosen K, Vince GH (2008) Expression of matrix metalloproteinases MMP-1, MMP- 11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res 60: 40-49.
• Szklarczyk A, Lapinska J, Rylski M, McKay RD, Kaczmarek L (2002) Matrix metalloproteinase-9 undergoes expres¬sion and activation during dendritic remodeling in adult hippocampus. J Neurosci 22: 920-930.
• Vaillant C, Didier-Bazes M, Hutter A, Belin MF, Thomasset N (1999) Spatiotemporal expression patterns of metallo- proteinases and their inhibitors in the postnatal develop¬ing rat cerebellum. J Neurosci 19: 4994-5004.
• Victorov IV, Prass K, Dirnagl U (2000) Improved selective, simple and contrast staining of acidophilic neurons with vanadium acid fuchsin. Brain Res Protocols 5: 135-139.
• Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson G, Younkin SG, Ashe KH (2002) The relationship between Ap and memory in the Tg2576 mouse model of Alzheimer's dis¬ease. J Neurosci 22: 1858-1867.
• Yamaguchi Y, Kawashima S (2001) Effects of amyloid-p- (25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol 412: 265-272.
• Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid p protein: reversal by tachykinin neuropeptides. Science 250: 279-282.
• Yin K-J, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu F-F, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee J-M (2006) Matrix metalloproteinas- es expressed by astrocytes mediate extracellular amyloid-p peptide catabolism. J Neurosci 26: 10939-10948.
• Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR (1998) Matrix metalloproteinases and diseases of the central nervous system. Trends Neurosci 21: 75-80.
• Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the ner¬vous system. Nat Rev Neurosci 2: 502-511.
• Yoshiyama Y, Asahina M, Hattori T (2000) Selective distri¬bution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol 99: 91-95.
• Zhang JW, Deb S, Gottschall PE (2000) Regional and age- related expression of gelatinases in the brains of young and old rats after treatment with kainic acid. Neurosci Lett 295: 9-12.